The 5.5 log10 REDUCTION in HCV levels, achieved with VX-950 and PEG-IFN, in 14 days, is the BEST BY FAR. Moreover, this was achieved in genotype 1 hepc patients -- the most difficult HCV genotype to treat effectively (and the most common in the US). In addition, in 50% of the patients, the HCV RNA could no longer be detected (below detection limit).
ALL THAT WAS ACHIEVED IN JUST 14 DAYS OF TREATMENT.
"VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a (Pegasys�; peg-IFN), achieved a rapid and dramatic reduction in plasma viral RNA levels in patients with chronic genotype 1 HCV infection. In this Phase Ib study, the combination of VX-950 and peg-IFN produced an initial median reduction in plasma HCV RNA of more than 3 log10 in the first two days, followed by continued decline to a median 5.5 log10 reduction in HCV RNA at day 14, which equates to a 300,000- fold reduction in viral levels. The majority of patients (6 of 8) receiving the combination achieved HCV RNA levels below the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan� assay) at 14 days, with 4 of 8 patients achieving HCV RNA levels below the limit of detection (10 IU/mL, Roche TaqMan�). The antiviral activity of the combination through 14 days was significantly greater than the activity of VX-950 administered as a single agent, and much greater than peg-IFN alone. In addition, VX-950 appeared to be well-tolerated when dosed alone and in combination with peg-IFN in the study. " (see link below)
Folks, the REAL ERA of VX-950 (and VRTX) has begun.
It will all be history soon.
"....Good thing VX950 didn't kill anyone."
That's the second time you have inferred that VX-950 MIGHT have killed someone. Why (short) are you (short) doing this?
As for your further questions ...err mistatements of fact---go look it up yourself. I'll even help you with a link: www.google.com.
"Tell that to the poor monkeys who GOT it!"
That is a comment towards BILN, not VRTX.
You shouldn't rely on others for the most basic of info. Your answer is easily found in the press release.
4 IFN control.
Do a little research before you criticize.
We got the answer to the 48 week issue. They will be doing a 48 week control arm, but only 3 months for 950 and IFN. My guess is, due to FT status, they will submit that data in pieces, and they did say that the FT does help them achieve their timeline, which they still say is for filing in 2008.
Gdubya, I guess the people you spoke with were referring to the control arm.
folks, rather than convincing the blind, take the time to listen to todays webcast
this company has a bright future based on multiple drug opportunities.
ps: will be averaging up a bit today
The more accurate interpretation depends on knowing the meaning of stymie:
"sty�mie also sty�my ( P ) Pronunciation Key (stm)
tr.v. sty�mied, (-md) sty�mie�ing, also sty�my�ing (-m-ng) sty�mies (-mz)
To thwart; stump: a problem in thermodynamics that stymied half the class."
Hence it is appropriate to say that Wind Waker has been stymied and is therefore a ____
VRTX did 2 cardiac tox studies in the earlier 1b, and there were no changes, it came out clean. SGP has done longer animal studies, and they were fine, otherwise they wouldn't be preceding. Nice try.